ArticleActa naturae
Tumor Necrosis Factor Inhibitors.
Article in Acta naturae. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-mediated inflammatory diseases affect a substantial proportion of the global population, and tumor necrosis factor (TNF) plays a central role in their pathogenesis. The most common diseases in clude rheumatoid arthritis (RA), Crohn's disease, psoriasis, multiple sclerosis, and septic shock. All of these conditions are characterized by excessive production of TNF, which activates downstream signaling pathways contributing to disease development and progression. To improve the quality of life in patients with TNF overproduction, anti-TNF agents such as TNF receptors and monoclonal antibodies are used. However, the availability of these therapies is limited. Therefore, the development of novel, more affordable TNF inhibi tors with comparable efficacy and improved safety remains a pressing issue. This review summarizes recent advances in the development of promising TNF inhibitors, including those derived from orthopoxvirus im munomodulatory proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.